Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZItm (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...
Some results have been hidden because they may be inaccessible to you